RECEIVED CENTRAL FAX CENTER

FEB 1 2 2008

Application No. 10/560,918 - - - - 2

AMENDMENTS TO THE CLAIMS

Claims 1-8 (canceled).

An isolated peptide consisting of the amino Claim 9 (previously presented). acid residue sequence CILGSDGEKNQCVTGEGTPKPESHNDGDFE (SEQ ID NO: 1) or a portion of SEQ ID NO: 1 consisting of at least 9 consecutive amino acid residues of SEQ ID NO: 1, and having a potential MHC class II binding activity, wherein said peptide has a stimulation index of > 1.8 in a biological assay of cellular proliferation and said index is taken as the value of cellular proliferation scored following stimulation by the peptide and divided by the value of cellular proliferation scored in control cells not in receipt of the peptide.

Claims 10-16 (canceled).

A pharmaceutical composition comprising Claim 17 (previously presented). the peptide of claim 9, optionally together with a pharmaceutically acceptable carrier, diluent or excipient.

An isolated peptide consisting of the amino acid residue Claim 18 (new). sequence CILGSDGEKNQCVTGEGTPKPESHNDGDFE (SEQ ID NO: 1).

A pharmaceutical composition comprising the peptide of Claim 19 (new). claim 18, optionally together with a pharmaceutically acceptable carrier, diluent or excipient.